Skip Navigation

JNCI Journal of the National Cancer Institute 2001 93(6):424-426; doi:10.1093/jnci/93.6.424-a
© 2001 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by McCann, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McCann, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 93, No. 6, 424-426, March 21, 2001
© 2001 Oxford University Press

NEWS

Cancer Drugs in Pipeline Span Wide Spectrum

Jean McCann

The pipeline for new treatments for cancer is bursting with agents of a different kind. The cytotoxic mainstays are still there, but new techniques for drug discovery have led to methods of targeting cancer cells with more precision and less toxicity.

The focus is on inducing apoptosis, inhibiting angiogenesis, and boosting the patient’s immune response to his or her tumor. At recent meetings in the United States and elsewhere, presentations of early results of agents in the pipeline, including vaccines, indicate potential for more . . . [Full Text of this Article]

Monoclonal Antibodies

Antiangiogenesis Drugs

Breast Cancer Drugs


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?